Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 23, Issue 8, 2011, Pages 980-987

  Nolan, Seonaid ^a   Milloy, M J ^a,b   Zhang, Ruth ^a   Kerr, Thomas ^a,b   Hogg, Robert S ^a   Montaner, Julio S G ^a,b   Wood, Evan ^a,b  

^a HIV/AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

adherence; highly active antiretroviral therapy (HAART); illicit drug use; injection drug user (IDU); virological suppression

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ABUSE; FEMALE; FOLLOW UP; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION DRUG USER; INTRAVENOUS DRUG ABUSE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; COHORT STUDIES; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960620004     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2010.543882     Document Type: Review

References (61)

1. Altice, F.L., Mezger, J.A., Hodges, J., Bruce, R.D., Marinovich, A., Walton, M., Friedland, G.H. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clinical Infectious Diseases, 38(Suppl. 5), S376-S387. (Pubitemid 38738534)
2. Andersen, R., Bozzette, S., Shapiro, M., St Clair, P., Morton, S., Crystal, S., Cunningham, W. (2000). Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research, 35(2), 389-416. (Pubitemid 30396962)
3. Anderson, K.H., & Mitchell, J.M. (2000). Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Archives of Internal Medicine, 160(20), 3114-3120.
4. Babudieri, S., Aceti, A., DOffizi, G.P., Carbonara, S., & Starnini, G. (2000). Directly observed therapy to treat HIV infection in prisoners. Journal of the American Medical Association, 284(2), 179-180. (Pubitemid 30460857)
5. Bangsberg, D.R., & Deeks, S.G. (2002). Is average adherence to HIV antiretroviral therapy enough? Journal of General Internal Medicine, 17(10), 812-813. (Pubitemid 35286248)
6. Boyd, M.A. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199.
7. Braithwaite, R.S., Kozal, M.J., Chang, C.C., Roberts, M.S., Fultz, S.L., Goetz, M.B., Justice (2007). Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS, 21(12), 1579-1589. (Pubitemid 47075479)
8. Bruce, R.D., & Altice, F.L. (2007). Clinical care of the HIV-infected drug user. Infectious Disease Clinics of North America, 21(1), 149-179, ix. (Pubitemid 46719806)
9. Chander, G., Himelhoch, S., & Moore, R.D. (2006). Substance abuse and psychiatric disorders in HIVpositive patients: Epidemiology and impact on antiretroviral therapy. Drugs, 66(6), 769-789. (Pubitemid 43765224)
10. Cortes, C., Beltran, C., Munoz, R., Daube, E., & Wolff, M. (2008). Impact of baseline CD4 count, immune recovery and viral suppression at 7 year of first highly active antiretroviral therapy on survival, AIDS defining events and immune recovery reactions. Revista Medica de Chile, 136(12), 1503-1510.
11. Danner, S.A., Carr, A., Leonard, J.M., Lehman, L.M., Gudiol, F., Gonzales, J., Pintado, V. (1995). A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. New England Journal of Medicine, 333(23), 1528-1533.
12. Diabate, S., Alary, M., & Koffi, C.K. (2007). Determinants of adherence to highly active antiretroviral therapy among HIV-1 infected patients in Cote d/Ivoire. AIDS, 21(13), 1799-1803. (Pubitemid 47237568)
13. Falster, K., Petoumenos, K., Chuah, J., Mijch, A., Mulhall, B., Kelly, M., & Cooper, D.A. (2009). Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. Journal of Acquired Immune Deficiency Syndromes, 50(3), 307-313.
14. Flexner, C. (1998). HIV-protease inhibitors. New England Journal of Medicine, 338(18), 1281-1292. (Pubitemid 28216584)
15. Glass, T.R., De Geest, S., Weber, R., Vernazza, P.L., Rickenbach, M., Furrer, H., Bucher, H.C. (2006). Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 41(3), 385-392.
16. Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S., Fischl, M.A. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine, 337(11), 725-733. (Pubitemid 27417971)
17. Harocopos, A., & Hough, M. (2005). Drug dealing in openair markets. Washington, DC: Office of Community-Oriented Policing Services, Department of Justice
18. Hecht, F., Colfax, G., Swanson, M., & Chesney, M. (1998, February 1-5). Adherence and effectiveness of protease inhibitors in clinical practice. Paper presented at the fifth conference on retrovirus and opportunistic infections, Chicago, IL.
19. Hogg, R.S., Heath, K., Bangsberg, D., Yip, B., Press, N., OShaughnessy, M.V., & Montaner, J.S. (2002). Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS, 16(7), 1051-1058. (Pubitemid 34499429)
20. Hogg, R.S., Yip, B., Kully, C., Craib, K.J., OShaughnessy, M.V., Schechter, M.T., & Montaner, J.S. (1999). Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal, 160(5), 659-665. (Pubitemid 29149796)
21. Karon, J.M., Fleming, P.L., Steketee, R.W., & De Cock, K.M. (2001). HIV in the United States at the turn of the century: An epidemic in transition. American Journal of Public Health, 91(7), 1060-1068. (Pubitemid 32574829)
22. Low-Beer, S., Yip, B., OShaughnessy, M.V., Hogg, R.S., & Montaner, J.S. (2000). Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes, 23(4), 360-361. (Pubitemid 30327043)
23. Markowitz, M., Saag, M., Powderly, W.G., Hurley, A.M., Hsu, A., Valdes, J.M., Leonard, J.M. (1995). A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine, 333(23), 1534-1539.
24. Mathers, B.M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S.A., Mattick, R.P. (2008). Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet, 372(9651), 1733-1745.
25. Mimiaga, M.J., Safren, S.A., Dvoryak, S., Reisner, S.L., Needle, R., & Woody, G. (2010). "We fear the police, and the police fear us": Structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care, 22(11), 1305-1313.
26. Mitty, J.A., Stone, V.E., Sands, M., Macalino, G., & Flanigan, T. (2002). Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clinical Infectious Diseases, 34(7), 984-990. (Pubitemid 34229768)
27. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., dArminio Monforte, A., Lundgren, J.D. (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362(9377), 22-29. (Pubitemid 36835816)
28. Palepu, A., Tyndall, M.W., Joy, R., Kerr, T., Wood, E., Press, N., Montaner, J.S. (2006). Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug and Alcohol Dependence, 84(2), 188-194. (Pubitemid 44119095)
29. Palepu, A., Tyndall, M.W., Yip, B., OShaughnessy, M.V., Hogg, R.S., & Montaner, J.S. (2003). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32(5), 522-526. (Pubitemid 36423124)
30. Palepu, A., Yip, B., Miller, C., Strathdee, S.A., OShaughnessy, M.V., Montaner, J.S., & Hogg, R.S. (2001). Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS, 15(3), 423-424. (Pubitemid 32163834)
31. Paris, D., Ledergerber, B., Weber, R., Jost, J., Flepp, M., Opravil, M., Zimmerli, S. (1999). Incidence and predictors of virologic failure of antiretroviral tripledrug therapy in a community-based cohort. AIDS Research and Human Retroviruses, 15(18), 1631-1638.
32. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21-30. (Pubitemid 30432540)
33. Porter, K., Babiker, A., Bhaskaran, K., Darbyshire, J., Pezzotti, P., & Walker, A.S. (2003). Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet, 362(9392), 1267-1274. (Pubitemid 37324254)
34. Rosenberg, P.S. (1995). Scope of the AIDS epidemic in the United States. Science, 270(5240), 1372-1375.
35. Roux, P., Carrieri, P., Villes, V., Dellamonica, P., Poizot-Martin, I., Ravaux, I., MANIF 2000 cohort study group. (2008). The impact of methadone or buprenorphine treatment and ongoing injection in highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF 2000 cohort study. Addiction, 103(11), 1828-1836.
36. Safren, S.A., Otto, M.W., Worth, J.L., Salomon, E., Johnson, W., Mayer, K., & Boswell, S. (2001). Two strategies to increase adherence to HIV antiretroviral medication: Life Steps and medication monitoring. Behaviour Research and Therapy, 39(10), 1151-1162. (Pubitemid 32743136)
37. Samet, J.H., Libman, H., Steger, K.A., Dhawan, R.K., Chen, J., Shevitz, A.H., Craven, D.E. (1992). Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A crosssectional study in a municipal hospital clinic. American Journal of Medicine, 92(5), 495-502.
38. Shapiro, M.F., Morton, S.C., McCaffrey, D.F., Senterfitt, J.W., Fleishman, J.A., Perlman, J.F., Bozzette, S.A. (1999). Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association, 281(24), 2305-2315. (Pubitemid 29289823)
39. Sherer, R., Stieglitz, K., Narra, J., Jasek, J., Green, L., Moore, B., Cohen, M. (2002). HIV multidisciplinary teams work: Support services improve access to and retention in HIV primary care. AIDS Care, 14(Suppl 1), S31-S44.
40. Shtatland, E., Kleinman, K., & Cain, E. (2005, April 10-13). Model building in PROC PHREG with automatic variable selection and information criteria. Paper presented at the SUGI 30 proceedings, Philadelphia, PA.
41. Simoni, J.M., Amico, K.R., Pearson, C.R., & Malow, R. (2008). Strategies for promoting adherence to antiretroviral therapy: A review of the literature. Current Infectious Disease Reports, 10(6), 515-521.
42. Small, W., Wood, E., Betteridge, G., Montaner, J., & Kerr, T. (2009). The impact of incarceration upon adherence to HIV treatment among HIV positive injection drug users: A qualitative study. AIDS Care, 21(6), 708-714.
43. Steiner, J.F., & Prochazka, A.V. (1997). The assessment of refill compliance using pharmacy records: Methods, validity, and applications. Journal of Clinical Epidemiology, 50(1), 105-116. (Pubitemid 27089212)
44. Stone, V.E., Jordan, J., Tolson, J., Miller, R., & Pilon, T. (2004). Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: Selfreport of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. Journal of Acquired Immune Deficiency Syndromes, 36(3), 808-816. (Pubitemid 38859346)
45. Strathdee, S.A., Palepu, A., Cornelisse, P.G., Yip, B., OShaughnessy, M.V., Montaner, J.S., Hogg, R.S. (1998). Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280(6), 547-549. (Pubitemid 28377675)
46. Strathdee, S.A., Patrick, D.M., Currie, S.L., Cornelisse, P.G., Rekart, M.L., Montaner, J.S., OShaughnessy, M.V. (1997). Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS, 11(8), F59-F65. (Pubitemid 27259515)
47. Tapper, M.L., Flexner, C., Eron, J.J., & Molina, J.M. (2004). Simplifying antiretroviral therapy. AIDS Read, 14(7), 355-360, 367-371.
48. Tebas, P., Royal, M., Fichtenbaum, C., Blutman, J., Arens, M., Horgan, M., & Powderly, W. (1998, February 1-5). Relationship between adherence to HAART and disease state. Paper presented at the fifth conference on retrovirus and opportunistic infections, Chicago, IL.
49. Thompson, M.A., Aberg, J.A., Cahn, P., Montaner, J.S., Rizzardini, G., Telenti, A., Schooley, R.T. (2010). Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association, 304(3), 321-333.
50. Tyndall, M.W., Currie, S., Spittal, P., Li, K., Wood, E., OShaughnessy, M.V., & Schechter, M.T. (2003). Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS, 17(6), 887-893. (Pubitemid 36547661)
51. Uhlmann, S., Milloy, M.J., Kerr, T., Zhang, R., Guillemi, S., Marsh, D., & Schechtern, M.T. (2010). Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction, 105(5), 907-913.
52. UNAIDS. (2009). Epidemic Update 2009. Joint Programme on HIV/AIDS. Geneva, Switzerland: UNAIDS.
53. Vanhove, G.F., Schapiro, J.M., Winters, M.A., Merigan, T.C., & Blaschke, T.F. (1996). Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association, 276(24), 1955-1956. (Pubitemid 26427720)
54. Vlahov, D., & Celentano, D.D. (2006). Access to highly active antiretroviral therapy for injection drug users: Adherence, resistance, and death. Cadernos de Saúde Pública, 22(4), 705-718.
55. Weber, R., Huber, M., Rickenbach, M., Furrer, H., Eliza, L., Hirschel, B., Swiss HIV Cohort Study. (2009). Uptake of and virological response to antiretroviral therapy among HIV infected former and current injecting drug users and persons in an opiate substitution treatment programme: The Swiss HIV cohort study. HIV Medicine, 10(7), 407-416.
56. Wood, E., Hogg, R.S., Bonner, S., Kerr, T., Li, K., Palepu, A., Montaner, J.S. (2004). Staging for antiretroviral therapy among HIV-infected drug users. Journal of the American Medical Association, 292(10), 1175-1177. (Pubitemid 39167404)
57. Wood, E., Hogg, R.S., Lima, V.D., Kerr, T., Yip, B., Marshall, B.D., & Montaner, J.S. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users. Journal of the American Medical Association, 300(5), 550-554.
58. Wood, E., Hogg, R.S., Yip, B., Harrigan, P.R., OShaughnessy, M.V., & Montaner, J.S. (2003). Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4-cell count is 0.200 to 0.350-10(9) cells/L. Annals of Internal Medicine, 139(10), 810-816.
59. Wood, E., Montaner, J.S., Tyndall, M.W., Schechter, M.T., OShaughnessy, M.V., & Hogg, R.S. (2003). Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. Journal of Infectious Diseases, 188(8), 1164-1170. (Pubitemid 37338981)
60. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., OShaughnessy, M.V., & Hogg, R.S. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169(7), 656-661. (Pubitemid 37266973)
61. Wood, E., Spittal, P.M., Small, W., Kerr, T., Li, K., Hogg, R.S., Schechter, M.T. (2004). Displacement of Canadas largest public illicit drug market in response to a police crackdown. Canadian Medical Association Journal, 170(10), 1551-1556. (Pubitemid 38686186)